Madrigal Pharmaceuticals, Inc. (MDGL): Price and Financial Metrics
GET POWR RATINGS... FREE!
MDGL Stock Price Chart Interactive Chart >
MDGL Price/Volume Stats
|Current price||$73.59||52-week high||$105.93|
|Prev. close||$71.58||52-week low||$52.33|
|Day high||$74.17||Avg. volume||215,674|
|50-day MA||$69.96||Dividend yield||N/A|
|200-day MA||$80.05||Market Cap||1.26B|
Madrigal Pharmaceuticals, Inc. (MDGL) Company Bio
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania.
Most Popular Stories View All
MDGL Latest News Stream
|Loading, please wait...|
MDGL Latest Social Stream
View Full MDGL Social Stream
Latest MDGL News From Around the Web
Below are the latest news stories about Madrigal Pharmaceuticals Inc that investors may wish to consider to help them evaluate MDGL as an investment opportunity.
Madrigal Pharmaceuticals (NASDAQ:MDGL) Q4 net loss increased to -$64.55M, compared to -$59.12M in Q4 2020. Q4 net interest income was $52K, compared to $432K in the prior year period. The company said the decreases in interest income for Q4 and FY 2021 was mainly due to lower average principal balances in...
Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results
CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today provides a summary of corporate accomplishments and reports its fourth quarter and full year 2021 financial results. Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “2021 was a year of significant progress for Madrigal as we continued to advance our industry-leadi
Madrigal Pharmaceuticals MDGL +15% liver disease candidate improved key patient outcomes in late-stage study.Yoshitsu Co (TKLF) +14%
Shares of clinical-stage biotech Madrigal Pharmaceuticals (NASDAQ: MDGL) rose by as much as 18% in pre-market action Monday morning. The gains came in response to a positive top-line readout from a phase 3 clinical trial for resmetirom, its experimental fatty liver disease drug candidate. Madrigal said that the drug was safe and well-tolerated at both the 80 mg and 100 mg dose levels assessed in the trial.
Madrigal shares rise, market cap surpasses $1B on positive late-stage study results for lead drug candidate
Founded in 2011, the Conshohocken company has grown to about 50 employees and is led by the husband-and-wife team.
MDGL Price Returns